Interstitial lung involvement in rheumatoid arthritis
https://doi.org/10.14412/1996-7012-2014-4-48-53
Abstract
Rheumatoid arthritis (RA) is a systemic autoimmune rheumatic disease of unknown etiology, characterized by chronic erosive arthritis and extraarticular manifestations. Pulmonary involvement is one of the common extraarticular manifestations of RA and may show itself as bronchial tree lesions, rheumatoid nodules, Caplan's syndrome, and lesions in the pleura or pulmonary interstitium (interstitial lung involvement (ILI)). High-resolution computed tomography allows the diagnosis of ILI in RA in nearly 70% of cases although the incidence of ILI may be lower (4 to 30%) depending on diagnostic methods and patient selection criteria. There are several histopathological types of ILI, the differential diagnosis of which can be troublesome. Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia are major types of RA-associated ILI. UIP-pattern ILI has a more severe course than ILI with other histological patterns. The clinical presentation of ILI may be complicated by the likely toxic effect of a number of disease-modifying antirheumatic drugs (DMARDs) used to treat RA, such as methotrexate and leflunomide, and biological agents (BAs), tumor necrosis factor-α (TNF-α) inhibitors. The pathogenesis of pulmonary involvement in RA and the role of synthetic DMARDs and BAs in the development of ILI call for further investigations.
An extraarticular manifestation, such as ILI, affects the choice of treatment policy in patients with RA.
The relevance of a study of ILI is beyond question. The paper discusses the state-of-the-art of investigations in this area.
About the Authors
David Vladimirovich Bestaev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow Russia 115522
T. D. Bestaeva
North-Ossetian State Medical Academy, Ministry of Health of Russia
Russian Federation
Russian Federation
40, Pushkinskaya St., Vladikavkaz, Republic of North Ossetia-Alania, Russia 362019
References
1. Насонов ЕЛ. Перспективы применения моноклональных антител к В–лимфоцитам (ритуксимаб) при ревматоидном артрите. Клиническая фармакология и терапия. 2006;1–5:55–8. [Nasonov EL. Perspective of administration of monoclonal antibodies to B-lymphocytes (rituximab) in rheumatoid arthritis in Russia. Klinicheskaya farmakologiya i terapiya. 2006;1–5:55–8. (In Russ.)].
2. Caporali R, Cavagna L, Montecucco C. Pain in arthritis. Eur J Pain Suppl. 2009;3(2):123–7. DOI:http://dx.doi.org/10.1016/j.eujps.2009.07.009.
3. Govoni M, Caporali R. Predicting and managing the progression of structural damage in rheumatoid arthritis: where do we stand? Clin Exp Rheumatol. 2012;30(4):459–63.
4. Krishnan E, Lingala B, Bruce B, Fries J F. Disability in rheumatoid arthritis in the era of biological treatments. Annals Rheum Dis. 2012;71(4):213–8. DOI: http://dx.doi.org/10.1136/annrheumdis-2011-200354.
5. Gabriel SE, Crowson CS, Kremers HM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum. 2003;48(1):54–8. DOI: http://dx.doi.org/10.1002/art.10705.
6. Cimmino MA, Salvarani C, Macchioni P, et al. Extra-articular manifestations in 587 Italian patients with rheumatoid arthritis. Rheumatol Int. 2000;19(6):213–7. DOI: http://dx.doi.org/10.1007/PL00006853.
7. Cavagna L, Boffini N, Cagnotto G, et al. Atherosclerosis and rheumatoid arthritis: more than a simple association. Mediators Inflamm. 2012;2012:147354. Epub 2012 Sep 13.
8. Turesson C. Extra-articular rheumatoid arthritis. Curr Opin Rheumatol. 2013;25(3):360–6. DOI: 10.1097/BOR.0b013e32835f693f.
9. Gauhar UA, Gaffo AL, Alarcon GS. Pulmonary manifestations of rheumatoid arthritis. Semin Respir Crit Care Med. 2007;28(4):430–40. DOI: 10.1055/s-2007-985664.
10. De Lauretis A, Veeraraghavan S, Renzoni E. Connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ? Chron Respir Dis. 2011;8(1):53–82. DOI: 10.1177/1479972310393758.
11. Ellman P, Ball R. Rheumatoid arthritis with joint and pulmonary manifestations. Br Med J. 1948;2(4583):816–20. DOI: 10.1136/bmj.2.4583.816.
12. Rubin EH. Pulmonary lesions in «rheumatoid disease» with remarks on diffuse interstitial pulmonary fibrosis. Am J Med. 1955;19(4):569–82. DOI: http://dx.doi.org/10.1016/0002-9343(55)90347-8.
13. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35(6):1322–8. DOI: 10.1183/09031936.00092309.
14. Ascherman DP. Interstitial lung disease in rheumatoid arthritis. Curr Rheumatol Rep. 2010;12(5):363–9 DOI: 10.1007/s11926-010-0116-z.
15. Hunninghake GW, Fauci AS. Pulmonary involvement in the collagen vascular diseases. Am Rev Respir Dis. 1979;119(3):471–503.
16. Cervantes-Perez P, Toro-Perez AH, Rodriguez-Jurado P. Pulmonary involvement in rheumatoid athritis. J Am Med Association. 1980;243(17):1715–9. DOI: 10.1001/jama.243.17.1715.
17. Nogee LM, Dunbar AE, Wert SE, et al. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. New Engl J Med. 2011;344(8):573–9. DOI: 10.1056/NEJM200102223440805.
18. Grutters JC, du Bois RM. Genetics of fibrosing lung diseases. Eur Respir J. 2005;25(5):915–27. DOI: 10.1183/09031936.05.00133404.
19. Mori S, Koga Y, Sugimoto M. Different risk factors between interstitial lung disease and airway dsease in rheumatoid arthritis. Respir Med. 2012;106(11):1591–9. DOI: 10.1016/j.rmed.2012.07.006.
20. Saag KG, Kolluri S, Koehnke RK, et al. Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities. Arthritis Rheum. 1996;39(10):1711–9.
21. Koduri G, Norton S, Young A, et al. Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology (Oxford). 2010;49(8):1483–9. DOI: 10.1093/rheumatology/keq035.
22. Young A, Koduri G. Extra-articular manifestations and complications of rheumatoid arthritis. Best practice and research. Clin Rheumatol. 2007;21(5):907–27. DOI: 10.1016/j.berh.2007.05.007.
23. Bongartz T, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis – a population-based study. Arthritis Rheum. 2010;62(6):1583–91. DOI: 10.1002/art.27405.
24. Toyoshima M, Chida K, Suda T, Sato M. Methotrexate might increase mortality from interstitial lung disease in rheumatoid arthritis. AM J Respir Crit Care Med. 2012;185(9):1024.
25. Inokuma S. Leflunomide-induced interstitial pneumonitis might be a representative of disease-modifying antirheumatic druginduced lung injury. Exp Opin Drug Safety. 2011;10(4):603–11. DOI: 10.1517/14740338.2011.560835.
26. Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum. 2011;41(2):256-64. DOI: 10.1016/j.semarthrit.2010.11.002.
27. Panopoulos ST, Sfikakis PP. Biological treatments and connective tissue disease associated interstitial lung disease. Curr Opin Pulm Med. 2011;17(5):362–7. DOI: 10.1097/MCP.0b013e3283483ea5.
28. Richman NC, Yazdany J, Graf J, et al. Extraarticular manifestations of rheumatoid arthritis in a multiethnic cohort of predominantly Hispanic and Asian patients. Medicine (Baltimore). 2013;92(2):92–7. DOI: 10.1097/MD.0b013e318289ce01.
29. AgustТ C. American thoracic society/European respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2002;165(2):277–304.
30. Tsuchiya Y, Takayanagi N, Sugiura H, et al. Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J. 2011;37(6):1411–7. DOI:10.1183/09031936.00019210.
31. Lee HK, Kim DS, Yoo BY, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest. 2005;127(6):2019–27. DOI: 10.1378/chest.127.6.2019.
32. Cavagna L, Caporali R, Abdi-Ali L, et al. Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease. J Rheumatol. 2013;40(4):484–92. DOI: 10.3899/jrheum.121026.
33. Manjunatha YC, Seith A, Kandpal H, Das CJ. Rheumatoid arthritis: spectrum of computed tomographic findings in pulmonary diseases. Curr Probl Diagn Radiol. 2010;39(6):235–46. DOI: 10.1067/j.cpradiol.2009.06.002.
34. Gutsche M, Rosen GD, Swigris JJ. Connective tissue disease-associated interstitial lung disease: a review. Curr Respir Care Rep. 2012;1(4):224–32. DOI: 10.1007/s13665-012-0028-7.
35. Myasoedova E, Crowson CS, Turesson C, et al. Incidence of extraarticular rheumatoid arthritis in olmsted county, Minnesota, in 1995–2007 versus 1985–1994: a populationbased study. J Rheumatol. 2011;38(6):983–9. DOI: 10.3899/jrheum.101133.
36. Bartels CM, Bell CL, Shinki K, et al. Changing trends in serious extra-articular manifestations of rheumatoid arthritis among united state veterans over 20 years. Rheumatology (Oxford). 2010;49(8):1670–5. DOI: 10.1093/rheumatology/keq135.
37. Habib HM, Eisa AA, Arafat WR. Marie M. Pulmonary involvement in early rheumatoid arthritis patients. Clin Rheumatol. 2011;30(2):217–21. DOI: 10.1007/s10067-010-1492-5.
38. Young A, Koduri G, Batley M, et al. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford). 2007;46(2):350–7. DOI: 10.1093/rheumatology/kel253.
39. Khan EA, Stamp LK, O'Donnell JL, Chapman PT. Cardiovascular morbidity in rheumatoid arthritis patients in North Canterbury, New Zealand 1999–2008. Int J Rheum Dis. 2013;16(1):19–23.
40. Olson AL, Swigris JJ, Sprunger DB, et al. Rheumatoid arthritis-interstitial lung diseaseassociated mortality. Am J Respir Crit Care Med. 2011;183(3):372–8. DOI: 10.1164/rccm.201004-0622OC.
41. Hamblin MJ, Horton MR. Rheumatoid arthritis-associated interstitial lung disease: diagnostic dilemma. Pulm Med. 2011;2011:872120. DOI: 10.1155/2011/872120.
42. Stolt P, KКllberg H, Lundberg I, et al. Silica exposure is associated with increased risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann Rheum Dis. 2005;64(4):582–6. DOI: 10.1136/ard.2004.022053.
43. Caplan A. Certain unusual radiological appearances in the chest of coal-miners suffering from rheumatoid arthritis. Thorax. 1953;8(1):29–37.
44. Schreiber J, Koschel D, Kekow J, et al. Rheumatoid pneumoconiosis (Caplan's syndrome). Eur J Intern Med. 2010:21(3):168–72. DOI: 10.1016/j.ejim.2010.02.004.
45. Yahya A, Bengtsson C, Lai TC, et al. Smoking is associated with an increased risk of developing ACPA-positive but not ACPAnegative rheumatoid arthritis in Asian populations: evidence from the Malaysian MyEIRA case-control study. Mod Rheumatol. 2012;22(4):524–31. DOI: 10.1007/s10165-011-0544-2.
46. Mikuls TR, Sayles H, Yu F, et al. Associations of cigarette smoking with rheumatoid arthritis in African Americans. Arthritis Rheum. 2010;62(2):3560–8. DOI: 10.1002/art.27716.
47. Hutchinson D, Shepstone L, Moots R, et al. Heavy cigarette smoking is strongly associated with rheumatoid arthritis (RA), particularly in patients without a family history of RA. Ann Rheum Dis. 2001;60(3):223–7. DOI: 10.1002/art.27716.
48. Thorley AJ, Tetley TD. Pulmonary epithelium, cigarette smoke, and chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2007;2(4):409–28.
49. Balbi B, Cottin V, Singh S, et al. Smoking-related lung diseases: a clinical perspective. Eur Respir J. 2010;35(2):231–3. DOI: 10.1183/09031936.00189309.
50. Vassallo R, Ryu JH. Smoking-related interstitial lung diseases. Clin Chest Med. 2012;33(1):165–8. DOI: 10.1183/09031936.00189309.
51. Westedt ML, Hazes JMW, Breedveld FC, et al. Cigarette smoking and pulmonary diffusion defects in rheumatoid arthritis. Rheumatol Int. 1998;18(1):1–4. DOI: 10.1007/s002960050045.
52. Saag KG, Kolluri S, Koehnke RK, et al. Rheumatoid arthritis lung disease: determinants of radiographic and physiologic abnormalities. Arthritis Rheum. 1996;39(10):1711–9.
53. Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med. 2008;168(2):159–66. DOI: 10.1001/archinternmed.2007.59.
54. Sakaida H. IgG rheumatoid factor in rheumatoid arthritis with interstitial lung disease. Ryumachi. 1995;35(4):671–7.
55. Alexiou I, Germenis A, Koutroumpas A, et al. Anti-cyclic citrullinated peptide-2 (CCP2) autoantibodies and extra-articular manifestations in Greek patients with rheumatoid arthritis. Clin Rheumatol. 2008;27(4):511–3. DOI: 10.1007/s10067-007-0800-1.
56. Aubart F, Crestani B, Nicaise-Roland P, et al. High levels of anti-cyclic citrullinated peptide autoantibodies are associated with co-occurrence of pulmonary diseases with rheumatoid arthritis. J Rheumatol. 2011;38(6):979–82. DOI: 10.3899/jrheum.101261.
57. Inui N, Enomoto N, Suda T, et al. Anticyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthritis. Clin Biochem. 2008;41(13):1074–7. DOI: 10.1016/j.clinbiochem.2008.06.014.
58. Fischer A, Solomon JJ, du Bois RM, et al. Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respir Med. 2012;106(7):1040–7. DOI: 10.1016/j.rmed.2012.03.006.
59. Gizinski AM, Mascolo M, Loucks JL, et al. Rheumatoid arthritis (RA)-specific autoantibodies in patients with interstitial lung disease and absence of clinically apparent articular RA. Clin Rheumatol. 2009;28(5):611–3. DOI: 10.1007/s10067-009-1128-9.
60. Bongartz T, Cantaert T, Atkins SR, et al. Citrullination in extra-articular manifestations of rheumatoid arthritis. Rheumatology (Oxford). 2007;46(1):70–5. DOI: 10.1093/rheumatology/kel202.
61. Harlow L, Rosas IO, Gochuico BR, et al. Identification of citrullinated hsp90 isoforms as novel autoantigens in rheumatoid arthritisassociated interstitial lung disease. Arthritis Rheum. 2013;65(4):869–79. DOI: 10.1002/art.37881.
62. Klareskog L., MalmstrЪm V., Lundberg K, et al. Smoking, citrullination and genetic variability in the immunopathogenesis of rheumatoid arthritis. Semin Immunol. 2011;23(2):92–8. DOI: 10.1016/j.smim.2011.01.014.
63. Saravanan V, Kelly C. Drug-related pulmonary problems in patients with rheumatoid arthritis. Rheumatology (Oxford). 2006;45(7):787–9. DOI: 10.1093/rheumatology/kel075.
64. Furukawa H, Oka S, Shimada K. HLA-A*31:01 and methotrexate-induced interstitial lung disease in Japanese rheumatoid arthritis patients: a multidrug hypersensitivity marker? Ann Rheum Dis. 2013;72(1):153–5. DOI: 10.1371/journal.pone.0033133.
65. Shidara K, Hoshi D, Inoue E, et al. Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort, IORRA. Mod Rheumatol. 2010;20(3):280–6.
66. Ju JH, Kim SI, Lee JH, et al. Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis. Arthritis Rheum. 2007;56(6):2094–6. DOI: 10.1002/art.22666.
67. Chikura B, Lane S, Dawson JK. Clinical expression of leflunomide-induced pneumonitis. Rheumatology (Oxford). 2009;48(9):1065–8. DOI: 10.1093/rheumatology/kep050.
68. Sawada T, Inokuma S, Sato T, et al. Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford). 2009;48(9):1069–72. DOI: 10.1093/rheumatology/kep052.
69. Martin N, Innes JA, Lambert CM, et al. Hypersensitivity pneumonitis associated with leflunomide therapy. J Rheumatol. 2007;34(9):1934–7.
70. Namba T, Tanaka K, Ito Y, et al. Induction of EMT-like phenotypes by an active metabolite of leflunomide and its contribution to pulmonary fibrosis. Cell Death Differ. 2010;17(12):1882–95. DOI: 10.1038/cdd.2010.64.
71. Hinz B, Phan SH, Thannickal VJ, et al. The myofibroblast: one function, multiple origins. Am J Pathol. 2007;170(6):1807–16. DOI: 10.2353/ajpath.2007.070112.
72. Peno-Green L, Lluberas G, Kingsley T, Brantley S. Lung injury linked to etanercept therapy. Chest. 2002;122(5):1858–60. DOI: 10.2353/ajpath.2007.070112.
73. Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum. 2011;41(2):256–64. DOI: 10.1016/j.semarthrit.2010.11.002.
74. Pearce F, Johnson SR, Courtney P. Interstitial lung disease following certolizumab pegol. Rheumatology (Oxford). 2012;51(3):578–80. DOI: 10.1093/rheumatology/ker309.
75. Caporali R, Pallavicini FB, Filippini M, et al. Treatment of rheumatoid arthritis with anti-TNF-α agents: a reappraisal. Autoimmun Rev. 2010;8(3):274–80. DOI: 10.1016/j.autrev.2008.11.003.
76. Montecucco C, Caporali R, Matucci-Cerinic M. Updating the Italian society for rheumatology recommendations for biologic therapy in adult patients with inflammatory rheumatic diseases. Clin Exp Rheumatology. 2011;29(3 Suppl.66):S3–6.
77. Schuller A, Coudurier M, Lega JC, et al. Interstitial lung disease and anti-TNF-α therapy in rheumatoid arthritis: two different patterns? Rev Mal Respir. 2010;27(3):232–7. DOI: 10.1016/j.rmr.2010.01.011.
78. Mori S, Imamura F, Kiyofuji C, Sugimoto M. Development of interstitial pneumonia in a rheumatoid arthritis patient treated with infliximab, an anti-tumor necrosis factor α-neutralizing antibody. Mod Rheumatol. 2006;16(4):251–5. DOI: 10.1007/s10165-006-0491-5.
79. Ye Q, Dai H, Sarria R, et al. Increased expression of tumor necrosis factor receptors in cryptogenic organizing pneumonia. Respir Med. 2011;105(2):292–7. DOI: 10.1016/j.rmed.2010.10.022.
80. Thomson EM, Williams A, Yauk CL, Vincent R. Overexpression of tumor necrosis factor-α in the lungs alters immune response, matrix remodeling, and repair and maintenance pathways. Am J Pathol. 2012;180(4):1413–30. DOI: 10.1016/j.ajpath.2011.12.020.
81. Mikami Y, Yamauchi Y, Horie M, et al. Tumor necrosis factor superfamily member LIGHT induces epithelial-mesenchymal transition in A549 human alveolar epithelial cells. Biochem Biophys Res Commun. 2012;428(4):451–7. DOI: 10.1016/j.bbrc.2012.10.097.
82. Sen S, Peltz C, Jordan K, Boes TJ. Infliximab-induced nonspecific interstitial pneumonia. Am J Med Sci. 2012;344(1):75–8. DOI: 10.1097/MAJ.0b013e31824c07e8.
83. Kuroki M, Noguchi Y, Shimono M, et al. Repression of bleomycin-induced pneumopathy by TNF. J Immunol. 2003;170(1):567–74.
84. Wynn T A. Fibrotic disease and the TH1/TH2 paradigm. Nature Rev Immunol. 2004;4(8):583–94.
85. Dixon WG, Hyrich KL, Watson KD, et al. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British society for rheumatology biologics register. Ann Rheum Dis. 2010;69(6):1086–91. DOI: 10.1136/ard.2009.120626.
86. Herrinton LJ, Harrold LR, Liu L, et al. Association between anti-TNF-α therapy and interstitial lung disease. Pharmacoepidemiol Drug Saf. 2013;22(4):394–402. DOI: 10.1002/pds.3409.
87. Vassallo R, Matteson E, Thomas CF Jr. Clinical response of rheumatoid arthritisassociated pulmonary fibrosis to tumor necrosis factor-α inhibition. Chest. 2002;122(3):1093–6. DOI: 10.1378/chest.122.3.1093.
88. Bargagli E, Galeazzi M, Rottoli P. Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis. Eur Respir J. 2004;24(4):708. DOI: 10.1183/09031936.04.00076904.
89. Antoniou KM, Mamoulaki M, Malagari K, et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheumatol. 2007;25(1):23–8.
90. Wang Y, Xu SQ, Xu JH, Ding C. Treatment with etanercept in a patient with rheumatoid arthritis-associated interstitial lung disease. Clin Med Insights Case Reps. 2011;4:49–52. DOI: 10.4137/CCRep.S8150.
91. Horai Y, Miyamura T, Shimada K, et al. Eternacept for the treatment of patients with rheumatoid arthritis and concurrent interstitial lung disease. J Clin Pharm Ther. 2012;37(1):117–21. DOI: 10.1111/j.1365-2710.2010.01234.x.
92. Komiya K, Ishii H, Fujita N, et al. Adalimumab-induced interstitial pneumonia with an improvement of pre-existing rheumatoid arthritis-associated lung involvement. Intern Med. 2011;50(7):749–51. DOI: 10.2169/internalmedicine.50.4748.
93. Wagner SA, Mehta AC, Laber DA. Rituximab-induced interstitial lung disease. Am J Hematol. 2007;82(10):916–9. DOI: 10.1002/ajh.20910.
94. Ram R, Ben-Bassat I, Shpilberg O, et al. The late adverse events of rituximab therapy – rare but there! Leuk Lymphoma. 2009;50(7):1083–95. DOI: 10.1080/10428190902934944.
95. Wu Y, Jia Y, Xu J, et al. Fatal interstitial lung disease induced by rituximab-containing chemotherapy, treatment with TNF-α antagonist and cytokine profiling: a case-report and review of the literature. J Clin Pharm Ther. 2013;38(3):249–53. DOI: 10.1111/jcpt.12052.
Review
For citations:
Bestaev DV, Bestaeva TD. Interstitial lung involvement in rheumatoid arthritis. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2014;8(4):48-53. (In Russ.) https://doi.org/10.14412/1996-7012-2014-4-48-53
Views:
1620
Email this article 